Literature DB >> 24653556

Study on anti-osteosarcoma activity of ethanol extract of Venenum bufonis in vitro.

Guangxing Chen1, Xuefeng Jiang2, Jingyi Li3, Guangjie Duan2, Liu Yang1, Ying Zhang1, Fuyou Wang1.   

Abstract

BACKGROUND: Venenum bufonis is the dried white secretion of the auricular and skin glands of Bufo gargarizans Cantor, or Bufo melanostictus Schneider, Bufonidae. It is used in the treatment of deep-rooted carbuncle, boils and swelling; pain in the throat, heart stroke, coma, abdominal pain, vomiting and diarrhea. The objective of this paper is to preliminarily observe the effects of ethanol extract of Venenum bufonis on growth, and proliferation of human osteosarcoma U2OS cell lines, and to provide a theoretical basis for an in-depth study of the clinical application of Venenum bufonis for osteosarcoma inhibition, with its mechanism of action.
MATERIALS AND METHODS: SRB assay was used to determine the effect of Venenum bufonis ethanol extract on U2OS cell line activity, and to detect its inhibitory dose-effect on osteosarcoma cells. FCM was applied to determine the effect of Venenum bufonis ethanol extract on U2OS cell apoptosis and to perform cell cycle analysis.
RESULTS: As results, different Venenum bufonis ethanol extracts showed apparent concentration-effect relationships on U2OS cell lines. FCM analysis showed that it had a U2OS apoptosis promoting effect, which increased with increasing concentration. Cell cycle analysis revealed that the Venenum bufonis ethanol extract mainly arrested U2OS in the G0/G1 phase, preventing the cells from progressing to the S phase.
CONCLUSION: The study concluded that Venenum bufonis ethanol extract has an inhibitory effect on proliferation of osteosarcoma U2OS cells.

Entities:  

Keywords:  U2OS; Venenum bufonis; antitumor

Mesh:

Substances:

Year:  2013        PMID: 24653556      PMCID: PMC3957244     

Source DB:  PubMed          Journal:  Afr J Tradit Complement Altern Med        ISSN: 2505-0044


  7 in total

1.  Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery.

Authors:  Roby C Thompson; Edward Y Cheng; Denis R Clohisy; John Perentesis; Carlos Manivel; Chap T Le
Journal:  Clin Orthop Relat Res       Date:  2002-04       Impact factor: 4.176

2.  Long-term results after repeated surgical removal of pulmonary metastases.

Authors:  D Kandioler; E Krömer; H Tüchler; A End; M R Müller; E Wolner; F Eckersberger
Journal:  Ann Thorac Surg       Date:  1998-04       Impact factor: 4.330

3.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

4.  Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience.

Authors:  M Szendroi; Z Pápai; R Koós; T Illés
Journal:  J Surg Oncol       Date:  2000-02       Impact factor: 3.454

5.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

Review 6.  Biology and therapeutic advances for pediatric osteosarcoma.

Authors:  Neyssa Marina; Mark Gebhardt; Lisa Teot; Richard Gorlick
Journal:  Oncologist       Date:  2004

7.  Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma.

Authors:  K Haselsberger; D C Peterson; D G Thomas; J L Darling
Journal:  Anticancer Drugs       Date:  1996-05       Impact factor: 2.248

  7 in total
  2 in total

1.  Study of Intravenous Single-Dose Toxicity Test of Bufonis venonum Pharmacopuncture in Sprague-Dawley Rats.

Authors:  Ki-Rok Kwon; Jun-Sang Yu; Seung-Ho Sun; Kwang-Ho Lee
Journal:  J Pharmacopuncture       Date:  2016-06

2.  Bufalin-loaded bovine serum albumin nanoparticles demonstrated improved anti-tumor activity against hepatocellular carcinoma: preparation, characterization, pharmacokinetics and tissue distribution.

Authors:  Huiqing Zhang; Nian Huang; Geliang Yang; Qing Lin; Yonghua Su
Journal:  Oncotarget       Date:  2017-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.